ImmunityBio Sued for Securities Law Violations

Contact DJS Law Group to Discuss Your Rights as a Shareholder

Apr. 3, 2026 at 6:35am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a stack of legal documents, a gavel, and a pair of glasses, conceptually representing the legal proceedings and the importance of accountability in the financial markets.A legal case against a pharmaceutical company highlights the need for transparency and accuracy in public disclosures.Los Angeles Today

A class action lawsuit has been filed against ImmunityBio, Inc. (NASDAQ: IBRX) for allegedly making false and misleading statements about the capabilities of its Anktiva medication, resulting in violations of federal securities laws during the class period from January 19, 2026 to March 24, 2026. Shareholders who purchased IBRX stock during this time are encouraged to contact DJS Law Group to potentially serve as lead plaintiff and recover their losses.

Why it matters

This lawsuit highlights the importance of transparency and accuracy in public disclosures for publicly traded companies. Investors rely on companies to provide truthful information about their products and financial performance, and allegations of securities fraud can significantly impact shareholder value and erode public trust.

The details

According to the complaint, ImmunityBio made false and misleading statements about the capabilities of its Anktiva medication, which led to violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934. The class period runs from January 19, 2026 to March 24, 2026, and the deadline for shareholders to join the case is May 26, 2026.

  • The class period runs from January 19, 2026 to March 24, 2026.
  • The deadline for shareholders to join the case is May 26, 2026.

The players

ImmunityBio, Inc.

A biopharmaceutical company that develops immunotherapies for the treatment of cancer and infectious diseases.

DJS Law Group

A law firm that specializes in securities class actions, corporate governance litigation, and domestic/international M&A appraisals, representing some of the largest and most sophisticated hedge funds and alternative asset managers in the world.

Got photos? Submit your photos here. ›

What’s next

The judge will decide on May 26, 2026 whether to allow the case to proceed as a class action lawsuit.

The takeaway

This lawsuit highlights the importance of accurate and transparent disclosures by publicly traded companies, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the biopharmaceutical industry and the enforcement of securities laws.